Ototoxicity according to NCI CTC v2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intra‐arterial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intravenous platinum… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to modified Brock criteria with intravenous… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival (overall and event‐free) ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in tumour response with intra‐arterial platinum (good and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Renal toxicity / vomiting/ cardiotoxicity (all grade 3 or higher according to NCI CTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Quality of life · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Disease-free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in disease-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Dysgeusia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine led to lower dysgeusia (grade >= 2, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Cost (mean per-patient supportive care costs) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to lower xerostomia (grade >= 2, 0-4 scale) compared with no treatment/placebo (low certainty).
3 findings from 1 review
RR 0.35 [0.19, 0.67]
3 studies · 119 participants
Low
RR 0.70 [0.40, 1.23]
7 studies · 682 participants
Low
RR 0.66 [0.48, 0.92]
5 studies · 687 participants
Low
Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher allergic response (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review